<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630408</url>
  </required_header>
  <id_info>
    <org_study_id>AVID-LAVI</org_study_id>
    <nct_id>NCT01630408</nct_id>
  </id_info>
  <brief_title>The Effects of Active VItamin D on Left Atrial Volume Index</brief_title>
  <acronym>AVID-LAVI</acronym>
  <official_title>A Pilot Study of the Effects of Active VItamin D on Left Atrial Volume Index in Patients With Heart Failure and Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot feasibility study to determine the effects of an activated vitamin D compound&#xD;
      (paricalcitol) on heart structure (size) and function (ability to relax) in patients with&#xD;
      normal kidney function and a form of heart failure known as HFPEF (heart failure and&#xD;
      preserved ejection fraction). This study will also examine heart failure-related&#xD;
      hospitalizations and changes in cardiac-stretch and biological markers that are believed to&#xD;
      change along with heart size. Patients in this pilot study will be treated for a period of 48&#xD;
      weeks with paricalcitol at a dose previously approved by FDA (1 mcg per day) and followed-up&#xD;
      for 4 weeks after treatment is completed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is among the top ten causes of hospitalizations in the US. It is estimated&#xD;
      that ~40-50% of patients with HF have preserved ejection fraction (EF). Patients with heart&#xD;
      failure and preserved ejection fraction (HFPEF) have normal systolic function, but impaired&#xD;
      cardiac relaxation. The main causes of HFPEF include left-ventricular hypertrophy (LVH) and&#xD;
      hypertension, hypertrophic cardiomyopathy, aortic stenosis with a normal EF, coronary artery&#xD;
      disease and restrictive cardiomyopathies.&#xD;
&#xD;
      Only a few small clinical trials have tested therapeutic interventions in patients with&#xD;
      HFPEF, producing either small or negative effects. Relatively few drugs have effects on&#xD;
      cardiac relaxation and are not candidates for chronic use, as they may have significant side&#xD;
      effect profiles and/or are inconvenient to administer. Paricalcitol, an FDA-approved&#xD;
      activated form of vitamin D, has been shown to slow LVH progression and improve parameters&#xD;
      associated with diastolic function in animal models (see refs). Treatment with paricalcitol&#xD;
      has also been associated with decreased cardiovascular morbidity and mortality in a&#xD;
      historical cohort study of patients with end-stage renal disease (see refs).&#xD;
&#xD;
      This is a single-center, single-arm, pilot study in 20 patients with HFPEF and normal renal&#xD;
      function on stable medical therapy to evaluate the effects of paricalcitol on cardiac&#xD;
      structure and function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator decided not to pursue.&#xD;
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left atrial volume index (LAVI) by transthoracic echocardiography.</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>The analysis will include all patients with at least two echocardiographic studies (baseline and one follow up). The primary endpoint will be determined upon completion of the study (ie, when all enrolled patients have been treated for up to 48 weeks with study medication).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of and time-to-first heart failure-related hospitalizations</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall cardiac and non-cardiac mortality rates</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biological, inflammatory, LVH and strain biomarkers that have been linked to cardiovascular disease.</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>High-sensitivity troponin-T, NT-proBNP, high-sensitivity C-reactive protein, propeptide procollagen type I, ST-2, Galectin-3, GDF-15 and osteoprotegerin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in standard mineral metabolite parameters (calcium, phosphorus, calcium-phosphate-product and PTH)</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in self-reported Patient Global Assessment</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic function parameters (including E, A, IVRT, DT)</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tissue doppler parameters (including Ea, Aa)</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary venous inflow (including S, D, a reversal)</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac ejection fraction</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in end-diastolic and end-systolic left ventricular internal dimension</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol oral capsules (1 mcg per day for 48 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Paricalcitol oral capsules 1 mcg/day for 48 weeks</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>Zemplar®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign informed consent.&#xD;
&#xD;
          -  Willing and able to adhere to all study-related procedures, including study medication&#xD;
             regimen.&#xD;
&#xD;
          -  ≥ 18 years old.&#xD;
&#xD;
          -  Previous clinical diagnosis of heart failure with preserved ejection fraction: NYHA&#xD;
             Class II-IV.&#xD;
&#xD;
          -  Satisfy these echocardiographic criteria within the last year: Left ventricular&#xD;
             ejection fraction ≥ 50%, cardiac magnetic resonance or ventriculogram; Left atrial&#xD;
             size ≥ 4 cm in long axis or &gt; 5.2 cm in four chamber length; Septal wall thickness &gt;&#xD;
             1.2 cm (females) or 1.3 cm (males); Doppler evidence of moderate or severe diastolic&#xD;
             dysfunction (≥ Grade II) by transmitral inflow, pulmonary venous flow, color M-mode&#xD;
             and/or tissue Doppler (per European Society of Cardiology guidelines).&#xD;
&#xD;
          -  Experienced ≥ 1 of the following in last 12 months: Hospitalization for acute heart&#xD;
             failure (primary diagnosis); Long term treatment with loop diuretic; Mean pulmonary&#xD;
             capillary wedge pressure ≥ 16 mm Hg at catheterization for dyspnea; Left ventricular&#xD;
             end diastolic pressure (LVEDP) ≥ 19 mm Hg at catheterization for dyspnea; Acute&#xD;
             treatment with intravenous loop diuretic or hemofiltration.&#xD;
&#xD;
          -  On stable medical therapy in last 30 days before study entry (defined as no change in&#xD;
             angiotensin converting enzyme inhibitors [ACEI], angiotensin receptor blockers,&#xD;
             aldosterone inhibitors, beta-blockers or calcium channel blockers.&#xD;
&#xD;
          -  Satisfy these criteria at initial lab screening: Estimated glomerular filtration rate&#xD;
             (eGFR) ≥ 30 ml/min; Corrected serum Ca 8.0-10.0 mg/dL (2.0-2.5 mmol/L); Phos ≤ 5.2&#xD;
             mg/dL (1.68 mmol/L); Serum albumin ≥ 3.0 g/dL (30 g/L);&#xD;
&#xD;
          -  Negative serum pregnancy test for females of childbearing potential (within 2 weeks of&#xD;
             starting study treatment).&#xD;
&#xD;
          -  Women of childbearing potential must be practicing barrier/oral contraception during&#xD;
             study-related treatment, or be surgically sterile or one year post-menopausal, be&#xD;
             non-nursing and non-pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking &gt; 1,000 IU of vitamin D preparation daily within last 30 days.&#xD;
&#xD;
          -  Received activated vitamin D preparation including paricalcitol (Zemplar®),&#xD;
             doxercalciferol (Hectorol®) or calcitriol (Rocalctrol®, Calcijex®) within last 90 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  History of nephrolithiasis.&#xD;
&#xD;
          -  Poorly controlled hypertension (systolic blood pressure &gt; 180 mmHg and/or diastolic&#xD;
             blood pressure &gt; 110 mmHg at Screening; confirmed by repeat).&#xD;
&#xD;
          -  Secondary hypertension (i.e. renal artery stenosis, primary aldosteronism or&#xD;
             pheochromocytoma).&#xD;
&#xD;
          -  Severe hepatic impairment.&#xD;
&#xD;
          -  Use of known inhibitors (ie, ketoconazole) or inducers (ie, carbamazepine) of&#xD;
             cytochrome P450 3A (CYP3A) within 2 weeks prior to taking study drug.&#xD;
&#xD;
          -  HIV positive.&#xD;
&#xD;
          -  Condition with prognosis &lt; 1 year at study entry other than heart failure.&#xD;
&#xD;
          -  Significant valvular disease defined as moderate or severe aortic or mitral stenosis,&#xD;
             mitral or aortic regurgitation.&#xD;
&#xD;
          -  Infiltrative cardiac disease (sarcoid, amyloid, hemochromatosis, lymphoma, etc.).&#xD;
&#xD;
          -  Arrhythmogenic right ventricular cardiomyopathy.&#xD;
&#xD;
          -  Active myocarditis.&#xD;
&#xD;
          -  Constrictive or restrictive pericarditis.&#xD;
&#xD;
          -  Acute coronary artery disease symptoms defined as emergency department visit or&#xD;
             hospital admission with unstable angina, ST-elevation myocardial infarction (STEMI),&#xD;
             non-ST-elevation myocardial infarction (NSTEMI), percutaneous coronary intervention&#xD;
             (PCI) or coronary artery bypass graft (CABG) within 90 days before study entry.&#xD;
&#xD;
          -  Poor echocardiographic windows.&#xD;
&#xD;
          -  Current active treatment in another investigational study or participation in another&#xD;
             investigational study within 1 month before screening.&#xD;
&#xD;
          -  Active malignancies except in situ carcinoma of the cervix, localized squamous or&#xD;
             basal cell carcinoma of skin.&#xD;
&#xD;
          -  Other serious concurrent or recent medical or psychiatric condition which, in&#xD;
             Investigator's opinion, makes the patient unsuitable for participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hector Tamez, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ravi Thadhani, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>01886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16810-5. Epub 2007 Oct 17.</citation>
    <PMID>17942703</PMID>
  </reference>
  <reference>
    <citation>Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996 Apr 1;97(7):1577-88.</citation>
    <PMID>8601621</PMID>
  </reference>
  <reference>
    <citation>Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest. 1987 Jun;79(6):1706-12.</citation>
    <PMID>3034981</PMID>
  </reference>
  <reference>
    <citation>Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003 Jul 31;349(5):446-56.</citation>
    <PMID>12890843</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ravi Thadhani</investigator_full_name>
    <investigator_title>Director of Clinical Research in Nephrology</investigator_title>
  </responsible_party>
  <keyword>Preserved ejection fraction</keyword>
  <keyword>Left ventricular hypertrophy</keyword>
  <keyword>Activated vitamin D</keyword>
  <keyword>Cardiac lusitropic effect</keyword>
  <keyword>Hospitalizations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

